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Abstract 
Objectives: Non-melanoma skin cancer is the most common malignancy in US, with an 
annual incidence of in excess of 1.5 million cases. In the majority of cases, locoregional 
treatment is curative and systemic therapy is not indicated. Platinum-based chemotherapy 
regimens have been used most commonly in refractory cases. The use of cetuximab, a 
monoclonal antibody targeting epidermal growth factor receptor [EGFR], has been reported 
for skin cancer treatment. This current study evaluated eight cases of locally advanced and 
refractory basal cell or squamous cell cancers which were treated with cetuximab.  
Methods: This is a retrospective study on eight patients who had received cetuximab for 
treatment  of  cutaneous  carcinoma  since  2007  at  Southern  Illinois  University  School  of 
Medicine (SIU-SOM) Medical Oncology clinic. 
Results: Three of the four patients with basal cell carcinoma and two of the four patients with 
squamous cell carcinoma maintained remission on treatment.. The main side effect was ac-
neiform rash which required termination of treatment for one patient and dose reduction in 
another.  
Conclusion: The study indicates that cetuximab may have a beneficial role for patients with 
non-melanoma cutaneous carcinomas that are refractory to standard therapy. 
Key words: cetuximab, non-melanoma, skin cancer 
Introduction 
As  per  the  United  Nations  Environment  Pro-
gramme (UNEP), global incidence of non-melanoma 
skin cancer exceeds 2  million each year  [2]. With a 
10% decrease in stratospheric ozone, this number is 
being  expected  to  increase  by  300,000  annually  [2]. 
Seventy-five percent of the non-melanoma skin can-
cers are basal cell carcinomas (BCC), which are usu-
ally effectively treated with excision. The remaining 
are predominantly squamous cell carcinomas (SCC). 
Treatment  options  for  SCC  vary  depending  on  the 
severity of the disease, but surgical excision alone is 
generally adequate treatment. However, for high risk 
SCC patients, which include those with inadequately 
excised and recurrent lesions, lymph node metastasis, 
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and immunosuppression,  the current treatment rec-
ommendation is combined surgery and radiation [3]. 
Patients with high risk cutaneous SCC includes those 
with  inadequately  excised  and  recurrent  lesions, 
lymph node metastasis, and immunosuppression [3]. 
At  the  molecular  level,  over  expression  of  EGFR  is 
considered  a  predictive  factor  for  identification  of 
high-risk  SCC  [3].  The  combination  of  radiation 
treatment and surgery has reduced the rate of locore-
gional relapse by 20-25% [4]. As per Porceddu et al, 
patients  with  high-risk  pathologic  features  such  as 
multiple nodes, extra nodal spread, positive margins, 
and  perineural  and  vascular  invasion  will  benefit 
from  concurrent  platinum-based  chemotherapy  and 
radiation treatment [5]. Platinum-based chemothera-
py regimens have been used most commonly in re-
fractory cases. But, this is frequently a patient popu-
lation with advanced age and multiple co-morbidities, 
in which platinum-based regimens are least tolerated. 
Systemic  therapy  is  recommended  only  in  patients 
with refractory disease.  
Cetuximab is a chimeric human/murine mono-
clonal antibody that binds competitively to EGFR and 
prevents  activation  of  the  receptor  [6].  Considering 
the low side effect profile, interest in cetuximab as a 
treatment for non-melanoma skin cancer is growing 
area.  Compared  to  currently  approved  chemothera-
pies  for  skin  carcinomas,  it  is  well  tolerated.  Most 
adverse  skin  reactions  expected  with  this  treatment 
are cutaneous and include acneiform eruption, xero-
sis,  paronychia,  hair  changes,  telangectasia  and  hy-
perpigmentation. The most common adverse effect is 
acneiform rash which is seen in 50-100% of patients 
[7]. This is assumed to be due to interference with the 
physiological role of EGFR in the epidermis. There are 
reported  cases  of  severe  acneiform  rash,  mucositis 
and dermatitis in people treated with combined radi-
ation and cetuximab [8;9]. There is also one reported 
case of toxic epidermal necrolysis caused by cetuxi-
mab plus minocycline in a patient receiving chemo-
radiation  for  recurrent  squamous  cell  carcinoma  of 
head  and  neck  which  evolved  in  the  5th  week  of 
treatment with cetuximab [10]. 
Here,  we  evaluate  eight  cases  of  advanced 
squamous cell carcinoma or basal cell carcinoma pa-
tients treated with cetuximab. Among the eight pa-
tients, four were basal cell carcinoma and four were 
squamous cell carcinoma. 
Patients and Methods 
A  retrospective  analysis  was  performed  using 
the records of the SIU-S between the years 2007-2011. 
Local institutional board approval (exempt approval 
on 01/21/2010) was obtained before the beginning of 
the  study.  Eight  patients  were  identified  who  had 
received cetuximab for treatment of skin carcinoma. 
Collected  from  the  case  records  were  demographic 
data including age, co-morbidities, and family histo-
ry.  Tumor  characteristics  included  histology,  stage 
and  treatment  factors  included  previous  interven-
tions, dose and frequency of cetuximab, and adverse 
effects of cetuximab. Assessment of disease status was 
based  on  physical  examination  documented  in  the 
clinic notes and imaging studies. Complete and par-
tial remission (CR & PR) has been determined based 
on RECIST criteria except the fact that patients may or 
may  not  been  continuing  the  treatment  during  that 
time [11]. The follow-up period started from the date 
that treatment was initiated.  
Results 
Among  the  eight  patients  analyzed,  four  had 
basal cell carcinoma and four had squamous cell car-
cinoma. The median age of the patient cohort is 79 
(Table 1). 
 
 
Table 1: Patient characteristics. 
Characteristics  All patients  Basal cell 
carcinoma 
Squamous 
cell carcinoma 
Number of patients  8  4  4 
Median age  79 (38-89)  84 (45-87)  71.5 (38-89) 
History of Gorlin syn-
drome 
3  3  0 
Family history of skin 
cancer 
3  3  0 
History of immunosup-
pressant use 
2  0  2 
 
 
 
 Three of the four patients with BCC had Gorlin 
syndrome  with a significant family  history of basal 
cell carcinoma. The age group of these patients varied 
from 45-87, including three above the age of 80. All of 
the octogenarians had multiple medical problems and 
required multiple surgeries and excisions of basal cell 
carcinomas  that  had  resulted  in  deformities  in  the 
head and neck area. Except for one SCC patient who 
had received Carboplatin and Docetaxel chemother-
apy,  none  of  the  other  seven  patients  received  any 
prior chemotherapy. The fourth BCC patient, without 
a history of Gorlin Syndrome, had an aggressive basal 
cell  carcinoma  that  warranted  numerous  resections 
over  several  years  as  well  as  radiation  therapy.  He 
ultimately developed regional lymph node metastasis 
and was referred for further management of his pro- Journal of Cancer 2012, 3 
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gressive disease that was considered refractory to any 
further radiation or surgery.  
Four  patients,  aged  38  to  89,  had  recurrent 
squamous cell carcinoma with a history of multiple 
recurrences in the past. Two patients had lymph node 
metastasis. Two patients had a history of renal trans-
plantation and concomitant immunosuppression. One 
was  on  Mycophenolate  and  presented  with  a  right 
temple lesion that recurred four times. It was treated 
initially with surgery and combined cetuximab and 
radiation  for  the  second  recurrence.  The  third  and 
fourth  recurrences  were  also  treated  with  surgery. 
The other patient presented with a metastatic squa-
mous cell carcinoma of unknown primary with me-
diastinal  adenopathy,  neck  mass  and  pulmonary 
nodules.  He  failed  Carboplatin/  Docetaxel  chemo-
therapy  and  developed  progressive  disease  with  a 
pericardial effusion, necessitating a pericardial win-
dow.  He  was  placed  on  cetuximab  with  complete 
clearing  of his lesions.  He ultimately lost  his trans-
planted  kidney  due  to  infection.  His  transplanted 
kidney was surgically removed, and all of his immu-
nosuppression was stopped.  
 For five out of the 8 patients, the starting dose of 
cetuximab was 125 mg/m2 once a week. One of the 
patients  with  BCC  received  cetuximab  250  mg/m2 
once  a  week,  and  the  latter  dose  was  subsequently 
escalated to 300 mg/m2. The starting dose of cetuxi-
mab for 2 of the BCC patients was 125 mg /m2 once a 
month. The dose was gradually increased up to 250 
mg/m2 for one of the patients. One of the SCC pa-
tients started with cetuximab 250 mg/m2 once a week 
for eight weeks as induction treatment. The same pa-
tient  continued  maintenance  treatment  for  two  and 
half years as cycles of once a week treatment for four 
weeks with two weeks off. 
 The adverse reactions observed during therapy 
are outlined in Table 2. Five out of 8 patients (63%) 
experienced  grade  II  acneiform  skin  rash  as  a  side 
effect, which was usually noted after 2-3 treatments. 
One  patient  was  treated  with  steroids  and  minocy-
cline because the rash recurred after each treatment. 
Another  patient  required  premature  termination  of 
cetuximab due to persistent skin rash despite treat-
ment  with  steroids and minocycline. This latter pa-
tient was subsequently able to tolerate cetuximab with 
a 50% dose reduction when it was restarted for dis-
ease recurrence. For the remaining three patients, the 
grade II skin rash resolved with 2-3 weeks of minocy-
cline treatment. One patient experienced grade II fis-
suring of the skin and improved with topical medica-
tions. This patient later developed grade II skin in-
duration and grade III skin pain after two and half 
years of treatment and stopped therapy. Skin biopsy 
later proved nephrogenic systemic sclerosis. Grade I 
hypomagnesaemia  was  observed  in  two  patients. 
They  were  treated  with  magnesium  intravenously 
(IV) with each treatment.  
Among the four patients with BCC, fifty percent 
attained  complete  remission  (CR)  and  50%  attained 
partial remission (PR) with treatment. Three patients 
relapsed after stopping the treatment (2 CR and 1 PR) 
and currently have been placed back on cetuximab. 
One patient remains on maintenance treatment for the 
last  12  months  after  attaining  an  initial  partial  re-
sponse. Another patient had a local recurrence of the 
disease after a four-month hiatus from treatment and 
now  remains  on  maintenance  treatment.  The  third 
BCC patient had two recurrences after the first treat-
ment with cetuximab, which had to be discontinued 
after  four  cycles  secondary  to  skin  rash.  However, 
disease remission had been attained by that time. The 
first recurrence occurred two months after discontin-
uing  cetuximab  but  responded  to  reinstitution  of 
treatment  for  seven  months.  The  second  recurrence 
occurred after five months off therapy, but remission 
was obtained again with the reinitiation of cetuximab, 
and the patient has been on maintenance treatment 
for the last seven months. The fourth patient, who had 
a partial response with cetuximab, had a multifocal 
recurrence soon after being off treatment. He was then 
started on a multidrug chemotherapy regimen with 
5-Flurouracil,  carboplatin,  and  cetuximab.  He 
achieved a near complete response to three cycles of 
chemotherapy  but  therapy  was  stopped  due  to  his 
advanced  age  and  performance  status.  His  disease 
recurred several months later, and he chose to receive 
supportive care only at that point. The median fol-
low-up  for  the  BCC  patients  is  12  months.  Median 
disease-free  survival  was  1  month.  With  a  median 
follow up of 12 months, overall survival was 100%. 
Median  survival  is  not  yet  reached  (Table  3).
  Three of the four patients with SCC obtained a 
CR. One relapsed at 6 months following active treat-
ment, and the other two have been in remission for 
the past 3 years. The latter two patients had a renal 
transplant and had previously been on Mycopheno-
late  or  other  immunosuppression.  The  patients  had 
been off the immunosuppressant for the past 3 years. 
The patient who had a partial response died second-
ary  to  other  co-morbidities  before  any  further  fol-
low-up. Median follow-up and disease- free survival 
were 32.5 months and 20.5 months, respectively. Over 
the 30 months follow up period, the overall survival 
was 75%. Median survival has not been reached (Ta-
ble 3).   Journal of Cancer 2012, 3 
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Table 2: Adverse effects. 
Side effects  Grade 1  Grade 2  Grade 3 & 4  Total Number 
Skin rash*  3/8 (37.5%)  2/8 (25%)  0  5 (62.5%) 
Hypomagnesemia*  2/8 (25%)  0  0  2/8 (25%) 
Skin fissuring*  0  1/8 (12.5%)  0  1/8 (12.5%) 
* number of patients. 
 
Table 3: Follow up data. 
Parameters  All patients  Basal cell carcinoma  Squamous cell carcinoma 
Median follow up  17 months  12 months  32.5 months 
Complete remission*  5/8 (62.5%)  2/4 (50%)  3/4 (75%) 
Partial remission*  3/8 (37.5%)  2/4 (50%)  1/4 (25%) 
Relapse*  5/8 (62.5%)  3/4 (75%)  2/4 (50%) 
Median disease free survival  4 months  1 month  20.5 months 
Median overall survival  Not reached  Not reached  Not reached 
* number of patients. 
 
 
Discussions 
This study shows that recurrent non-melanoma 
skin cancers can be successfully treated with extended 
cetuximab therapy. 62.5 percent of the study patients 
obtained a complete remission and a major response 
(CR  and  PR)  was  achieved  in  all  of  the  patients. 
However,  among  those  whose  treatment  was  held, 
63%  of  the  patients  subsequently  relapsed.  For  the 
three  patients  who  had  a  sustained  remission,  two 
have continued the maintenance treatment, and the 
other one has stopped. Our median disease-free sur-
vival was only 4 months. Over the 17 months median 
follow  up  period,  the  overall  survival  is  88%.  The 
median  overall  survival  has  not  yet  been  reached. 
Among the total group, 63% and 25% of patients had 
grade II skin rash and grade 1 hypomagnesemia, re-
spectively. 13% of the patients experienced grade II 
fissuring. The skin induration and skin pain experi-
enced by one patient were considered to be unrelated 
adverse events. No other adverse events were noted, 
and no one developed grade III or IV toxicities with 
treatment.  
Epidermal  growth  factor  receptor  [EGFR]  is  a 
member  of  tyrosine  kinase  growth  factor  receptor 
family. Activation of this receptor results in intracel-
lular tyrosine kinase autophosphorylation, which ini-
tiates  a  cascade  of  intracellular  events  ultimately 
leading  to  cell  cycle  progression,  angiogenesis,  me-
tastasis and reduced apoptosis [12]. EGFR is normally 
expressed in human cells, but higher levels of expres-
sion have been shown in many malignancies. As per 
Krahn, 80% of SCC and 57% of BCC express EGFR 
[13].  As  per  previous  studies,  aberration  in  EGFR 
pathways is associated with poor prognosis in many 
malignancies. Even though BCC also expresses EGFR, 
the  key  pathology  in  BCC  is  an  aberration  in  the 
hedgehog  pathway  [14;15].  Novel  inhibitors  of  this 
pathway such as GDC-0449 are on trial but are not yet 
clinically approved [16]. It has been shown that EGFR 
signaling  acts  synergistically  with  the  hedgehog 
pathway  in  the  malignant  transformation  of  cells 
[17;18]. This may explain the effectiveness of cetuxi-
mab in patients with BCC. 
We were able to obtain either a CR or a PR for all 
of our patients. However, we had a significant relapse 
rate for patients when treatment was stopped, which 
emphasizes the importance of maintenance treatment 
for  long-term  disease  control.  Even  though  median 
disease  free  survival  was  only  one  month,  overall 
survival over the 30 month follow up period was 75%. 
All of these patients had refractory disease, and we 
were able to prolong their life with a relatively low 
toxicity treatment regimen. 
 Compared  to  currently  approved  chemothera-
pies for skin carcinomas, cetuximab is well tolerated. 
In  our  study,  the  most  commonly  experienced  side 
effect  was  acneiform  skin  rash  occurring  in  63%  of 
patents, which is consistent with a prior study [7]. All 
of skin rashes were grade II in severity, which were 
treated  successfully  with  steroids  and  minocycline. 
Concurrent  radiation  treatment  increases  the  inci-
dence of serious adverse events as per the case reports 
that  we  discussed  earlier.  Only  one  of  our  patients  Journal of Cancer 2012, 3 
 
http://www.jcancer.org 
261 
had received radiation treatment along with cetuxi-
mab  treatment,  and  he  subsequently  responded  to 
single agent cetuximab therapy along with immuno-
suppressant modulation. 
 There have been isolated case reports of using 
cetuximab  in  recurrent  non-melanoma  skin  cancers 
with  favorable  responses  [19-22].  However,  there 
have been no studies comparing efficacy of treatment 
with  cetuximab  versus  currently  approved  chemo-
therapeutic  agents  for  cutaneous  malignancies.  The 
results of the above reported cases are encouraging 
for the use of cetuximab in refractory non-melanoma 
skin cancers and suggest that a randomized phase III 
study between chemotherapy and cetuximab in this 
condition may be useful. 
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